Clinical trials: Health Adult Subjects
Polycystic Ovary Syndrome
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
An investigation of the safety and efficacy of tildacerfont in women with PCOS and elevated adrenal androgens
- Trial name
- NCT05370521
- Testing
- Tildacerfont
- Where
- 21 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spruce Biosciences
Chronic Otitis Media
Retrospective Health Care Utilisation and Current Quality of Life in Adults With Chronic Otitis Media Who Had a Middle Ear Surgery
The objective of this multicentre study is to evaluate the standard of care of participants diagnosed with Chronic Otitis Media that have already gone through a first middle ear surgery but still have at least a moderate hearing…
- Trial name
- NCT04864912
- Testing
- Questionnaires and survey
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 69 people
- Sponsor
- Cochlear
Healthy Subjects
Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.
This study will test the safety, tolerability and blood concentrations of single and multiple oral doses of PF-06751979 in health subjects and healthy elderly subjects.
- Trial name
- NCT02793232
- Testing
- PF-06751979 single dose, PF-06751979 multiple ascending dose, PF-06751979 multiple dose
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pfizer
Spondylitis, Ankylosing
Study Comparing Etanercept (ETN) Against a Placebo for Etanercept on a Background Nonsteroidal Anti Inflammatory Drug (NSAIDs) in the Treatment of Early Spondyloarthritis (SpA) Patients Who do Not Have X-ray Structural Changes
This is a two part study. During period one there will be a comparison of Etanercept (ETN) against a placebo with both arms maintaining the background anti inflammatory drug prescribed by their Physician.
- Trial name
- EMBARK (NCT01258738)
- Testing
- etanercept, Background NSAID
- Where
- 50 sites in Argentina, Belgium and 12 more
- Volunteers
- 225 people
- Sponsor
- Pfizer
Seasonal Allergic Rhinitis
A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
The study objective is to investigate the efficacy of levocetirizine in reducing symptoms associated with seasonal allergic rhinitis and in improving rhinitis-related Quality of Life
- Trial name
- NCT00621959
- Testing
- levocetirizine dihydrochloride
- Where
- 26 sites in United States
- Volunteers
- 596 people
- Sponsor
- UCB Pharma
Typhoid Fever
Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)
This trial is aimed to evaluate the safety and immunogenicity profiles of three formulations of Vi-CRM197 conjugate vaccine against S.
- Trial name
- NCT01193907
- Testing
- NVGH Vi-CRM197 12.5 mcg, NVGH Vi-CRM197 5.0 mcg, NVGH Vi-CRM197 1.25 mcg
- Where
- Belgium
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novartis
Seasonal Allergic Rhinitis
A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
The study objective is to investigate the efficacy of levocetirizine in reducing symptoms associated with seasonal allergic rhinitis and in improving rhinitis-related Quality of Life.
- Trial name
- NCT00653224
- Testing
- levocetirizine dihydrochloride
- Where
- 38 sites in United States
- Volunteers
- 580 people
- Sponsor
- UCB Pharma
Schizophrenia, Mental Disorder
Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole
The purpose of this study is to determine the usability of the Medical Information Device #1 (MIND1) system in adults with schizophrenia who are treated with oral aripiprazole.
- Conditions
- Schizophrenia, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02219009
- Testing
- MIND1 System
- Where
- 6 sites in United States
- Volunteers
- 67 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.